Acute hepatopancreatic necrosis disease (AHPND) is a severe disease affecting recently stocked cultured shrimps. The disease is mainly caused by V. parahaemolyticus that harbors the pVA1 plasmid; this plasmid contains the pirA and pirB genes, which encode a delta-endotoxin. AHPND originated in China in 2009 and has since spread to several other Asian countries and recently to Latin America (2013). Many Asian strains have been sequenced, and their sequences are publicly accessible in scientific databases, but only four strains from Latin America have been reported. In this study, we analyzed nine pVA1-harboring V. parahaemolyticus sequences from strains isolated in Mexico along with the 38 previously available pVA1-harboring V. parahaemolyticus sequences and the reference strain RIMD 2210633. The studied sequences were clustered into three phylogenetic clades (Latin American, Malaysian, and Cosmopolitan) through pangenomic and phylogenomic analysis. The nucleotide sequence alignment of the pVA1 plasmids harbored by the Asian and Latin American strains confirmed that the main structural difference in the plasmid between the Asian and Latin American strains is the absence of the Tn3 transposon in the Asian strains; in addition, some deletions in the pirAB region were found in two of the Latin American strains. Our study represents the most robust and inclusive phylogenomic analysis of pVA1-harboring V. parahaemolyticus conducted to date and provides insight into the epidemiology of AHPND. In addition, this study highlights that disease diagnosis through the detection of the pirA and pirB genes is an inadequate approach due to the instability of these genes.
Montalvo, S, Gonzalez, MP, Dietze-Hermosa, MS, Martinez, A, Rodriguez, S, Gomez, M, Ibarra-Mejia, G, Tan, E, and Dorgo, S. Effects of different stretching modalities on the antagonist and agonist muscles on isokinetic strength and vertical jump performance in young men. J Strength Cond Res 39(2): 173-183, 2025-Exercise warm-up may include static or dynamic stretching, impacting performance differently. This study investigated the effects of various stretching protocols on isokinetic strength, muscular activity, and vertical jump performance. Sixteen subjects, divided evenly between trained and untrained groups, underwent 8 distinct stretching conditions in random order. Outcomes measured included isokinetic knee extension and flexion torque and power, muscular activity (vastus lateralis, vastus medialis, and biceps femoris), and jump performance (jump height and modified reactive strength index [RSImod]). Responses to the stretching conditions were analyzed using a mixed-methods approach. For isokinetic knee extension, dynamic stretching of both agonist and antagonist (DY-AG-ANT) and combined dynamic agonist with static antagonist stretching (DY-AG ST-ANT) produced significant improvements. Dynamic stretching of both agonist and antagonist increased peak torque by 12.72% and average torque by 30.80%, while DY-AG ST-ANT increased peak torque by 15.61% and average torque by 41.06%. Muscular activity also improved significantly; DY-AG ST-ANT increased EMG activity of the vastus lateralis by 29.43% and vastus medialis by 70.75%. Biceps femoris saw a 33.18% increase with DY-AG and a 22.15% increase with ST-AG. Countermovement jump height improved with DY-AG-ANT (12.6%) and static antagonist (ST-ANT) conditions (11.3%) ( p < 0.05). Dynamic stretching of both agonist and antagonist also enhanced average power knee extension by 32.41%, while ST-AG DY-ANT improved it by 31.09% ( p < 0.05). Dynamic stretching, especially when combined with static stretching, optimizes isokinetic strength, muscular activity, and jump height. Coaches should incorporate dynamic stretching, alone or with static antagonist stretching, to maximize performance.
COVID-19 has caused great devastation in the past year. Multi-organ point-of-care ultrasound (PoCUS) including lung ultrasound (LUS) and focused cardiac ultrasound (FoCUS) as a clinical adjunct has played a significant role in triaging, diagnosis and medical management of COVID-19 patients. The expert panel from 27 countries and 6 continents with considerable experience of direct application of PoCUS on COVID-19 patients presents evidence-based consensus using GRADE methodology for the quality of evidence and an expedited, modified-Delphi process for the strength of expert consensus. The use of ultrasound is suggested in many clinical situations related to respiratory, cardiovascular and thromboembolic aspects of COVID-19, comparing well with other imaging modalities. The limitations due to insufficient data are highlighted as opportunities for future research.